Chamber and committees

The Scottish Government’s position has been, and remains, focussed on the ‘whole cancer pathway’ which is why the 62-day standard is in place. This covers the period from an urgent suspicion of cancer (USC) referral from a primary care clinician to the start of treatment for Scotland’s most common cancers, including ovarian cancer.

The latest published statistics (July-September 2023) show the median time for an ovarian cancer patient from USC referral to first treatment is 51 days. Once a decision to treat is made, the median wait for treatment is 12 days for ovarian cancer patients.

Scottish Government officials meet with Boards’ Cancer Management Teams fortnightly (monthly for Island Boards) to ensure patients are moving timeously through these pathways and are treated as quickly as possible. Where cancer pathway challenges are identified, innovative solutions are explored and best practice shared from other areas.

We are investing £40 million over five years to support cancer services, with £10 million provided to Boards in 2023-24 alone.

The Deputy National Clinical Director and Scottish Government officials met with the clinical leads for ovarian cancer in the Northern Cancer Alliance (NCA) and the South East Scotland Cancer Network (SCAN) during Summer 2023.

Ongoing improvements to the service, including waiting times for treatment, and any potential support required from the Scottish Government were discussed.

The Scottish Government wants cancer patients to be treated as close to home as clinically appropriate. However, as treatments for some cancers become more complex and expensive, it becomes impossible to deliver them in every location.

Cancer services require a highly specialised workforce. In order to ensure the future sustainability of our services, we published our ten-year Cancer Strategy in which we have committed to modelling cancer workforce requirements and continue to grow the number of training places to expand our workforce.

As part of the Scottish Government’s work to develop a sustainable healthcare workforce, we continue to look for opportunities to increase levels of recruitment and retention of healthcare staff in rural areas and will develop a Rural Workforce Recruitment Strategy by the end of 2024. This will support employers to ensure that the health and social care needs of people, including women with ovarian cancer who live in rural communities, are met.

The Scottish Government is committed to working with NHS Boards to deliver our ambition to protect, stabilise and recover planned care. This includes maximising theatre productivity, optimising capacity and regional working.

Regional cancer networks have undertaken, and continue to undertake, improvement work to reduce ovarian cancer surgery waits. This improvement work includes increasing surgery provision and regional support.

The Scottish Cancer Network will be establishing a new National Ovarian Cancer Clinical Network, which will work to ensure equity of access to treatment for all women with ovarian cancer in Scotland.

I refer the member to the answer to question S6W-23323 on‎ 11 December 2023. All answers to written parliamentary questions are available on the Parliament’s website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers

The Scottish Government has listened to concerns that independent hospices have about the recruitment and retention of staff, and will continue to do so.

As Integration Joint Boards (IJBs) are responsible for the governance, planning, and resourcing of adult palliative care services, including hospices, using the integrated budget under their control, we will continue to work with Chief Officers to support longer term sustainable planning and commissioning for the hospice sector, and will work jointly to develop a national guidance framework to support and improve consistency of local planning and commissioning.

The Digital Prescribing and Dispensing Pathways (DPDP) Programme is being developed, and it is intended to replace the paper prescription with a digital solution in community settings. The programme has been commissioned and funded by the Scottish Government. It is being jointly delivered by NHS National Services Scotland (NSS) and NHS Education for Scotland (NES) in collaboration with stakeholders across Scotland.

The inclusion of prescriptions for stoma items has been raised by the Chief Pharmaceutical Officer with the DPDP programme team, and consideration is being given as to how stoma items can be brought within the scope of the programme.

There is no specific provision for long COVID research in the Scottish Government Budget for 2024-25.

Within the Scottish Government, funding of Health and Care Research comes under the remit of the Chief Scientist Office (CSO).

The CSO's Translational Clinical Studies (TCS) Committee and the Health Improvement, Protection and Services Research (HIPS) Committee each meet twice per year to consider funding applications. Details of the application process are published on the CSO website.

https://www.cso.scot.nhs.uk/grant-funding/response-mode-funding-schemes/

Applications on long-COVID are welcomed. In common with all other applications, these would go through the CSO's standard independent peer review process.

To date 2 research projects on long COVID have been funded via this route:

HIPS/23/08

Long COVID And Frontline Public Service Occupations: Impacts On Employees And Organisations

University of Stirling

Dr Alice MacLean/Professor Kate Hunt

Funding awarded £296,960

HIPS/22/33

Caring for Long COVID in Primary Care: Using Patient and Professional Experience to Build Co-Designed Solutions. A Participatory, Mixed Methods Study.

University of Glasgow

Professor Catherine O’Donnell

Funding awarded £297,900

Through UK-wide funding agreements, researchers based in Scotland are able to access the following research funding programmes administered by the National Institute for Health & Care Research (NIHR):

Efficacy and Mechanism Evaluation (EME)

Evidence Synthesis

Health and Social Care Delivery Research (HSDR)

Health Technology Assessment (HTA)

Invention for Innovation (i4i)

Programme Development Grants (PDG)

Programme Grants for Applied Research (PGfAR)

Public Health Research (PHR)

Research for Social Care (RfSC)

Within their individual remits, the above programmes can consider applications for research in long COVID.

CSO is working with the health research community in Scotland to ensure awareness of these opportunities and to maximise the number of high quality applications from Scotland to these research funding programmes going forward.

As the Deputy First Minister set out in her Budget Statement on 19 December 2023, the financial position across Scottish Government is extremely challenging and work is ongoing to identify measures to address the continued challenges in 2024-25 and beyond.

Integration Joint Boards are responsible for the governance, planning, and resourcing of adult palliative care services, including hospices, using the integrated budget under their control. We will therefore continue to work with Integration Joint Boards and independent hospices to explore solutions and options for longer term sustainable planning and commissioning for the independent hospice sector.

The Scottish Government remains committed to ensuring that everyone who needs it can access seamless, timely and high-quality palliative care.

We are currently developing a new National Strategy for Palliative and End of Life Care for Scotland. As part of this work, we are reviewing the information and evidence we have, and need, to develop the strategy. This includes gathering data on current and projected needs for palliative care at a population level, mapping governance, services and support across Scotland, and building on our understanding of people’s experiences of palliative and end of life care.

The outputs of this work will give us a clearer picture of the delivery and accessibility of palliative care across Scotland, and will inform a new strategy that reflects what really matters to people experiencing serious illness, dying and bereavement.